There are currently 1332 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Emory University Hospital/Winship Cancer Institute and Children's Health Care of Atlanta. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549
Recruiting
The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/22/2025
Locations: Children's Healthcare of Atlanta - Center for Advanced Pediatrics, Atlanta, Georgia
Conditions: Obesity, Overweight
Register for Updates
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
NCT06611163
Recruiting
Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Dermatology Affiliates Research Institute, LLC, Atlanta, Georgia
Conditions: Moderate to Severe Genital Psoriasis
Register for Updates
A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension
NCT06608901
Recruiting
This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on adult patients (18 to 85 years) hospitalized due to a serious infection (called "sepsis") and receiving standard-of-care medications for low blood pressure (called "vasopressors") due to sepsis. The aim of the study is to see how safe, tolerable, and effective the study drug is by observing the effects on blood pressure and the total amount of vasopressor dose received during your stay... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/22/2025
Locations: Emory University Hospital, Atlanta, Georgia
Conditions: Sepsis-Induced Hypotension
Register for Updates
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
NCT06741228
Recruiting
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
07/22/2025
Locations: Atlanta Center for Medical Research, Atlanta, Georgia
Conditions: Generalized Anxiety Disorder
Register for Updates
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT06739122
Recruiting
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/22/2025
Locations: Children's Healthcare of Atlanta - Center for Advanced Pediatrics, Atlanta, Georgia
Conditions: Type 2 Diabetes
Register for Updates
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
NCT06672939
Recruiting
The main purpose of this study, performed under Master Protocol J4M-MC-PWMP, is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the study will last about 18 months.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
07/22/2025
Locations: Children's Healthcare of Atlanta - Center for Advanced Pediatrics, Atlanta, Georgia
Conditions: Obesity, Overweight
Register for Updates
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
NCT06894212
Recruiting
This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants with Schizophrenia
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/22/2025
Locations: Synexus Clinical Research US Inc - Atlanta Site #148, Atlanta, Georgia +1 locations
Conditions: Schizophrenia
Register for Updates
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
NCT07000123
Recruiting
This is a study to evaluate the efficacy and safety of AZD0780 in adults with clinical ASCVD or who are at risk for a first ASCVD event and who have elevated LDL-C. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Research Site, Atlanta, Georgia +1 locations
Conditions: Cardiovascular Disease
Register for Updates
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
NCT06809595
Recruiting
A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
07/22/2025
Locations: Atlanta Center for Medical Research, Atlanta, Georgia
Conditions: Generalized Anxiety Disorder
Register for Updates
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
NCT06791122
Recruiting
This study is open to people aged 18 years or older with schizophrenia. People can join the study if they are willing to use a smartphone app called CT-155. This app is being developed to help people with schizophrenia manage their negative symptoms. The purpose of this study is to gather new information on CT-155. Researchers want to see how well it works, how well participants use the study app, and how it affects the use of health care services. Participants use the app for 16 weeks. They m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Emory University, Atlanta, Georgia
Conditions: Schizophrenia
Register for Updates
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
NCT06223360
Recruiting
The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
07/21/2025
Locations: Emory University Goizueta Alzheimer's Disease Research Center(GADRC), Atlanta, Georgia
Conditions: Alzheimer Disease
Register for Updates
Trans-auricular Vagal Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease
NCT07090668
Recruiting
The goal of this study is to evaluate the effects of transauricular vagal nerve stimulation on the treatment of pain in children with Sickle Cell Disease. * The primary objective is to determine the feasibility of using a taVNS device to treat pain in pediatric participants with SCD by assessing the completion rate, stimulation tolerability, and acceptability of the intervention measures. * The secondary objective is to assess the preliminary efficacy of using a taVNS device as a remedy for pai... Read More
Gender:
ALL
Ages:
Between 7 years and 18 years
Trial Updated:
07/21/2025
Locations: Children's Hospital of Atlanta: Eagelston, Atlanta, Georgia
Conditions: Sickle Cell Disease
Register for Updates